Skip to main content
All Posts By

Clinic Hours

2025 AHA hypertension guidelines: Key updates for clinical practice

Blood Pressure Categories & Treatment Targets

The guideline retains the 2017 definitions of blood pressure categories:

  • Normal: < 120/80 mm Hg
  • Elevated: 120–129 / < 80 mm Hg
  • Stage 1 Hypertension: 130–139 or 80–89 mm Hg
  • Stage 2 Hypertension: ≥ 140 or ≥ 90 mm Hg

The treatment goal for all adults remains < 130/80 mm Hg.

Risk Assessment & Personalized Care

The new PREVENT™ risk calculator replaces the older pooled cohort equations. It estimates both 10- and 30-year cardiovascular risk and integrates cardiovascular, kidney, metabolic, and social health factors to personalize interventions.

Prevention, Lifestyle & Brain Health

The guideline emphasizes prevention of heart disease, stroke, kidney disease, and cognitive decline.
Lifestyle recommendations include:

  • Sodium intake < 2,300 mg/day (ideal < 1,500 mg)
  • DASH-style or heart-healthy diet
  • 75–150 minutes/week of aerobic and/or resistance activity
  • ≥ 5% weight loss if overweight
  • Stress management with meditation, breathing exercises, or yoga
  • Alcohol limitation: maximum 2 drinks/day (men), 1 (women)

Diagnostics & Laboratory Evaluation

  • Urine albumin-to-creatinine ratio is now recommended for all hypertensive patients to assess kidney health.
  • Plasma aldosterone-to-renin ratio screening is expanded to detect primary aldosteronism, especially in resistant hypertension or sleep apnea.

Medication Strategy

  • Stage 2 hypertension: Start with two medications, preferably as a single-pill combination.
  • Recommended classes: ACE inhibitors, ARBs, long-acting dihydropyridine CCBs, and thiazide-type diuretics.
  • In patients with overweight or obesity, GLP-1 receptor agonists may be considered as an adjunct.

Special Considerations: Hypertension in Pregnancy

  • Initiate antihypertensive therapy when BP reaches ≥ 140/90 mm Hg.
  • Postpartum women with pregnancy-associated hypertension should have annual BP checks.

Low-dose aspirin (81 mg/day) may be considered to reduce the risk of preeclampsia.

Reference: AHA
Clinical Inshorts by ClinicHours

Ruxolitinib outperforms best available therapy in chronic GVHD

A phase 3, randomized, open-label trial of 329 patients (≥12 years) with steroid-refractory/dependent chronic graft-vs-host disease (SR/D-cGVHD) found that ruxolitinib significantly extended median failure-free survival (FFS) to 38.4 months versus 5.7 months with best available therapy (BAT) (HR 0.36).

At 36 months, 59.6% of ruxolitinib-treated patients maintained response vs 26.7% with BAT. Among BAT patients who crossed over, the week-24 overall response rate was 50%, with best overall response reaching 81.4%. Nonrelapse mortality was slightly lower with ruxolitinib (17.8% vs 22.0%).

The treatment showed sustained efficacy and manageable safety over 3 years, though some long-term endpoints (like quality of life) couldn’t be fully assessed due to dropouts.

Study led by Robert Zeiser, MD; funded by Novartis and Incyte; published June 25 in Journal of Clinical Oncology.

Clinical Inshorts by ClinicHours

Enlarged thymus at 2 months linked to higher risk of Atopic Dermatitis

Infants with a larger thymus at 2 months of age had a significantly higher risk—over sixfold—for developing atopic dermatitis (AD) by age 2. The risk remained high—over fivefold—for early-onset AD before 6 months.

Study Overview: A prospective study of 300 full-term infants at Rigshospitalet, Copenhagen (2017–2019) tracked thymus size via ultrasound at birth, 2 months, and 12 months. AD severity was assessed using the Eczema Area and Severity Index (EASI). Out of 300, 290 infants completed the 2-year follow-up.

Results:

  • AD prevalence by age 2: 34.1%

  • High thymic index at 2 months:

    • 6.3x higher AD risk by age 2 (aHR: 6.32; P < .001)

    • 5.4x higher risk for early-onset AD (<6 months) (aHR: 5.35; P < .001)

  • Moderate correlation between thymic index and EASI score at 2 months (r = 0.39); no correlation at birth or 12 months.

Clinical Insight: The association held even after adjusting for filaggrin (FLG) gene mutations and family history, indicating thymic size may independently predict AD risk.

Source: Jacob P. Thyssen, MD, PhD, University of Copenhagen; study published online July 29 in Allergy.

Limitations: Findings may be limited by potential bias from AD overrepresentation, variability in ultrasound quality, and reliance on thymus size alone.

Funding & Disclosures: Supported by multiple foundations including LEO, Lundbeck, Novo Nordisk, and others. Some authors reported financial ties or employment with sponsors.

Clinical Inshorts by ClinicHours

ASTRO guidelines incorporate the 2021 WHO glioma reclassification

Glioblastoma (GBM), now classified as CNS WHO grade 4 adult-type diffuse glioma, is the most aggressive and common malignant brain tumor in adults. Despite advancements in surgery, radiation therapy (RT), and chemotherapy (notably temozolomide), prognosis remains poor—median survival is 15–17 months and <10% survive 5 years.

Historically, GBM classification relied solely on histology, but the 2021 WHO CNS classification incorporates molecular markers for more accurate diagnosis and prognosis. Key molecular features defining WHO grade 4 diffuse glioma include:

  • IDH-wildtype astrocytoma with:

    1. EGFR amplification

    2. Gain of chromosome 7/loss of chromosome 10

    3. TERT promoter mutation

  • CDKN2A/B homozygous deletion in IDH-mutant gliomas

These markers can now reclassify some tumors previously labeled as grade 2 or 3 into grade 4, even without necrosis or vascular proliferation.

Importantly, only IDH-wildtype tumors are now classified as GBM, whereas IDH-mutant grade 4 tumors are termed astrocytoma, IDH-mutant, WHO grade 4.

This updated ASTRO guideline replaces the 2016 version, aligning with modern molecular classifications and addressing disparities in care to guide future research and equitable treatment.

Clinical Inshorts by ClinicHours

Semaglutide emerges as a potential treatment for MASH

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).

Methods: In this phase 3 trial, 1197 patients with biopsy-confirmed MASH and liver fibrosis (stage 2 or 3) were randomly assigned to weekly semaglutide 2.4 mg or placebo. Interim results at 72 weeks from the first 800 patients are reported. Primary goals were resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis without worsening steatohepatitis.

Results: Semaglutide led to steatohepatitis resolution without fibrosis worsening in 62.9% of patients vs. 34.3% with placebo. Fibrosis improved without worsening steatohepatitis in 36.8% vs. 22.4%. Both outcomes occurred in 32.7% vs. 16.1%. Weight loss was greater with semaglutide (−10.5% vs. −2.0%). GI side effects were more common with semaglutide; pain scores were similar.

Conclusions: Semaglutide 2.4 mg weekly significantly improved liver histology in MASH patients with fibrosis.

Reference: NEJM
Clinical Inshorts by ClinicHours

New guidelines prioritize Iron over Dopamine in Restless Legs Syndrome

Restless Legs Syndrome (RLS) affects 8% of the population, mainly women. It causes an overwhelming urge to move the legs, especially in the evening or during rest, often with tingling or electric sensations. Movement temporarily relieves symptoms.

Previously, dopamine agonists (e.g., pramipexole, rotigotine, ropinirole) were first-line treatment. However, the American Academy of Sleep Medicine (AASM) now recommends against them due to augmentation syndrome—a worsening of symptoms with long-term use. France still permits their use in severe cases, per 2019 guidelines.

At a recent neurology conference in Montpellier, Dr. Sofiène Chenini emphasized non-dopaminergic options and warned against overuse.

Updated First-Line Therapies:

  • IV iron supplementation (when ferritin <75 µg/L) is now first-line.
  • Antiepileptics (gabapentin, pregabalin) are preferred for mild-to-moderate RLS or in cases with insomnia.
  • Lifestyle changes—avoiding caffeine, alcohol, smoking; regular sleep habits; and daytime exercise—can help mild cases.

If oral iron fails, IV options like ferric carboxymaltose or ferric hydroxide-sucrose are recommended. Mild opioids(e.g., codeine, tramadol) may be added if symptoms persist.

Diagnosis Criteria (SFRMS 2016)

  1. Urge to move legs with unpleasant sensations
  2. Worsens at rest
  3. Relieved by movement
  4. Worse at night
  5. No other underlying cause

RLS is linked to brain iron deficiency—MRI studies suggest impaired iron transport and dopamine/glutamate overactivity. Contributing factors include aging, certain medications (especially serotonergic antidepressants and antihistamines), and genetic predisposition.

Alternative antidepressants like venlafaxine or duloxetine (shorter half-life) are preferred if needed.

Misuse Drives Change

A U.S. registry of 670,000 RLS patients revealed 60% received dopamine agonists, and 20% exceeded recommended doses, especially among neurologists. Overprescription—often modeled on Parkinson’s protocols—prompted AASM’s guideline update.

Clinical Inshorts by ClinicHours

OMI & NOMI concept: Replacing the STEMI/NSTEMI terminologies

In 2018, Meyers, Weingart and Smith introduced us to the concept of Occlusion Myocardial Infarction (OMI). The term STEMI equivalent is already in our vocabulary, but it actually refers to patients with clinical and ECG features concerning for acute coronary occlusion who would benefit from immediate PCI.

Definition of OMI?

An ongoing ischemia resulting in irreversible infarction caused by complete or near-complete occlusion of a culprit epicardial coronary artery, with inadequate collateral circulation, thus necessitating immediate reperfusion.

Definition of NOMI?

No occlusion, or sufficient collateral circulation to avoid active infarction.

What’s wrong with the STEMI label?

Patients with acute occlusion not meeting STEMI criteria may be an underserved, underidentified subgroup of ACS patients who would benefit from emergent intervention, whereby classification of AMI by occlusion vs. no occlusion may be more appropriate than classification by ST elevation on the ECG. Meyers et al 2020

Example: A 70 year old female presents to ED with atypical chest pain. ECG done.


Explanation:

This ECG may appear normal to most of us, but it actually indicates an OMI. This ECG from @tbouthillet shows small hyperacute T waves in inferior leads concerning for early inferior OMI, demonstrated best by their size relative to the preceding QRS Complex.


OMI
 ECG Patterns not meeting STEMI criteria:

  • Wellens pattern A
  • Wellens pattern B
  • De Winter T-wave
  • New-onset bifascicular block
  • Modified Sgarbossa – Smith
  • Aslanger pattern
  • Posterior OMI
  • Precordial Swirl
  • Hyperacute T-wave
  • South African flag sign
  • Northern OMI

Mimics of OMI with ST Elevation:

References: https://omiguide.org/ | https://litfl.com/omi-replacing-the-stemi-misnomer/
Clinical Inshorts by ClinicHours

Human Metapneumovirus (HMPV) symptoms, diagnosis & treatment

Human metapneumovirus (HMPV) is a negative-sense ss RNA virus of the family Pneumoviridae. It was isolated for the first time in 2001 in the Netherlands. It is the second most common cause after RSV of acute respiratory tract illness.

Subtypes: Four lineages – A1, A2, B1 and B2.

Virology: HMPV infects airway epithelial cells in the nose and lung. It attaches to the target cell via the glycoprotein protein interactions with heparan sulfate and other glycosaminoglycans.

Incubation period: 3-6 days

Transmission: Contact with contaminated secretions, via droplet, aerosol, or  hospital acquired infections.

Symptoms: Cough, fever, runny or stuffy nose, sore throat, wheezing, SOB (dyspnea), rash.

Diagnosis: RT-PCR, Immunofluorescence assays, NAAT.

Rx: Supportive care, Ribavirin showed effectiveness in an animal model.

Prognosis: Most people with HMPV have mild URTI similar to the common cold and recover from HMPV in about 7 to 10 days without any complications.

Complications: Viral pneumonia, Bronchiolitis, A/E COPD, secondary bacterial infections.

HMPV outbreak in East Asia began with an outbreak of cases Beijing, China in December 2024. It was linked to 5.4 % of respiratory illness hospitalisations in China, more than COVID-19, rhinovirus or adenovirus. Cases were also reported in Malaysia, India, Pakistan and Kazakhstan.

Clinical Inshorts by ClinicHours

Indian Health Ministry approves BPaLM regimen for MDR TB

Indian Health Ministry approves introduction of new shorter and more efficacious treatment regimen for drug-resistant TB. BPaLM regimen consisting of 4 drug combination.


In December 2022 WHO also released a new treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline.

A 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended in place of the 9-month or longer (18-month) regimens in MDR/RR-TB patients, now including extensive pulmonary TB and extrapulmonary TB (except TB involving central nervous system, miliary TB and osteoarticular TB).

Use of 9-month all-oral regimen rather than 18-months regimen is suggested in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded.

Longer (18-month) treatments remain a valid option in all cases in which shorter regimens cannot be implemented due to intolerance, drug-drug interactions, extensively drug-resistant tuberculosis, extensive forms of extrapulmonary TB, or previous failure.

Reference: WHO, MoHFW
Clinical Inshorts by ClinicHours

Causes of sudden cardiac arrest

Causes of sudden cardiac arrest:

1. Cardiovascular pathology

  • Coronary artery disease (MC – 80% of all cases)
  • Severe left ventricular dysfunction

2. Cardiomyopathy (10-15% of all cases)

  • Hypertrophic cardiomyopathy
  • Arrhythmogenic right ventricular cardiomyopathy

3. Congenital heart disease

  • Anomalous left coronary artery from the pulmonary artery [ALCAPA] syndrome
  • Aortic stenosis
  • Aortic coarctation
  • Tetralogy of Fallot
  • Transposition of the great arteries
  • Ebstein’s anomaly
  • Single ventricle

4. Valvular heart disease

5. Cardiac pacemaker

6. Conducting system disease

  • Lenegre’s disease
  • Lev’s disease

7. Hereditary channelopathies (5-10% of all cases)

  • Brugada syndrome
  • Early repolarization syndrome
  • Long QT syndrome
  • Short QT syndrome
  • Catecholaminergic polymorphic ventricular tachycardia
Reference: Page 53-55, Tintinalli’s Emergency Medicine 9th Edition
Clinical Rounds by
ClinicHours
error: